Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Total Liabilities (2023 - 2025)

Historic Total Liabilities for Profound Medical (PROF) over the last 3 years, with Q3 2025 value amounting to $10.2 million.

  • Profound Medical's Total Liabilities fell 906.49% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 906.49%. This contributed to the annual value of $9.8 million for FY2024, which is 2293.43% down from last year.
  • As of Q3 2025, Profound Medical's Total Liabilities stood at $10.2 million, which was down 906.49% from $10.4 million recorded in Q2 2025.
  • Profound Medical's 5-year Total Liabilities high stood at $12.7 million for Q4 2023, and its period low was $12507.0 during Q1 2023.
  • Moreover, its 3-year median value for Total Liabilities was $10.8 million (2024), whereas its average is $10.1 million.
  • Over the last 5 years, Profound Medical's Total Liabilities had its largest YoY gain of 9204839.69% in 2024, and its largest YoY loss of 2293.43% in 2024.
  • Over the past 3 years, Profound Medical's Total Liabilities (Quarter) stood at $12.7 million in 2023, then decreased by 22.93% to $9.8 million in 2024, then rose by 3.57% to $10.2 million in 2025.
  • Its Total Liabilities was $10.2 million in Q3 2025, compared to $10.4 million in Q2 2025 and $10.1 million in Q1 2025.